← Back to Search
Indirubin Core Structure Of Glycogen Synthase Kinase-3 Inhibitors As Novel Chemotype For Intervention With 5-lipoxygenase.
C. Pergola, N. Gaboriaud-Kolar, Nadine Jestädt, Stefanie König, M. Kritsanida, A. M. Schaible, Haokun Li, Ulrike Garscha, C. Weinigel, D. Barz, K. Albring, O. Huber, A. L. Skaltsounis, O. Werz
Published 2014 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
The enzymes 5-lipoxygenase (5-LO) and glycogen synthase kinase (GSK)-3 represent promising drug targets in inflammation. We made use of the bisindole core of indirubin, present in GSK-3 inhibitors, to innovatively target 5-LO at the ATP-binding site for the design of dual 5-LO/GSK-3 inhibitors. Evaluation of substituted indirubin derivatives led to the identification of (3Z)-6-bromo-3-[(3E)-3-hydroxyiminoindolin-2-ylidene]indolin-2-one (15) as a potent, direct, and reversible 5-LO inhibitor (IC50 = 1.5 μM), with comparable cellular effectiveness on 5-LO and GSK-3. Together, we present indirubins as novel chemotypes for the development of 5-LO inhibitors, the interference with the ATP-binding site as a novel strategy for 5-LO targeting, and dual 5-LO/GSK-3 inhibition as an unconventional and promising concept for anti-inflammatory intervention.
This paper references
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
A. Koeberle (2008)
Structure based drug design, synthesis and evaluation of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives as 5-lipoxygenase inhibitors.
N. P. Reddy (2012)
On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance.
U. Siemoneit (2009)
Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3.
M. Brungs (1995)
Disease‐specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain
David F. Fischer (2003)
Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization.
J. Falgueyret (1995)
Targeting leukotriene B4 in inflammation
A. Di Gennaro (2014)
Improved purification of 12-lipoxygenase from rat basophilic leukemia cells and conditions for optimal enzyme activity.
E. M. van der Donk (1991)
Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3
M. Martin (2005)
Mechanisms of disease: Leukotrienes
M. Peters-Golden (2007)
Vascular Development in the Retina and Inner Ear Control by Norrin and Frizzled-4, a High-Affinity Ligand-Receptor Pair
Q. Xu (2004)
Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase
B. Hofmann (2008)
On the inhibition of 5‐lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo
C. Pergola (2012)
5-Lipoxygenase: regulation of expression and enzyme activity.
O. Rådmark (2007)
From Tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues.
K. Vougogiannopoulou (2012)
An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins.
Vassilios Myrianthopoulos (2007)
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
S. Laufer (1994)
GSK-3-selective inhibitors derived from Tyrian purple indirubins.
L. Meijer (2003)
Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.
O. Werz (2008)
7-Bromoindirubin-3′-oxime induces caspase-independent cell death
J. Ribas (2006)
The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5‐lipoxygenase products
L. Fischer (2007)
Glycogen synthase kinase-3beta inhibition attenuates asthma in mice.
Z. Bao (2007)
Methodology for the preparation of olive oil open ring secoiridoids
K. Vougogiannopoulou (2012)
GSK-3: tricks of the trade for a multi-tasking kinase
B. Doble (2003)
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.
Yiran Wu (2012)
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
R. Hoessel (1999)
3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.
Y. Ferandin (2006)
Phosphorylation‐ and stimulus‐dependent inhibition of cellular 5‐lipoxygenase activity by nonredox‐type inhibitors
L. Fischer (2003)
The tumor suppressor Fhit acts as a repressor of β-catenin transcriptional activity
J. Weiske (2007)
Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
K. Vougogiannopoulou (2008)
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
Eva-Maria Karg (2009)
High capacity for leukotriene biosynthesis in peripheral blood during pregnancy.
A. M. Schaible (2013)
Indirubin-3′-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration
Tina Blažević (2014)
Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin.
O. Werz (2007)
Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo
Christian Feisst (2009)
Analysis of a nucleotide-binding site of 5-lipoxygenase by affinity labelling: binding characteristics and amino acid sequences.
Y. Zhang (2000)
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
P. Polychronopoulos (2004)
Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases
Vassilios Myrianthopoulos (2013)
Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase.
Karin Meirer (2013)
5-Lipoxygenase inhibitors: a review of recent developments and patents
C. Pergola (2010)
This paper is referenced by
Isatin derivatives with activity against apoptosis-resistant cancer cells.
N. Evdokimov (2016)
Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.
J. Guo (2018)
Design, synthesis, and biological evaluation of (2E)-(2-oxo-1, 2-dihydro-3H-indol-3-ylidene)acetate derivatives as anti-proliferative agents through ROS-induced cell apoptosis.
Zhuang Song (2016)
TEMPO-catalyzed oxidative homocoupling route to 3,2′-biindolin-2-ones via an indolin-3-one intermediate
Bo Yin (2017)
A cascade synthetic route to new bioactive spiroindolinepyrido[1,2- a ]indolediones from indirubin
Alexander M Sele (2015)
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
A. Svouraki (2017)
Indirubin 3'-Epoxide Induces Caspase-Independent Cell Death in Human Neuroblastoma.
Masahiro Kurita (2016)
The Anterior Spreader Flap: A Minimally Invasive Alternative to the Auto Spreader Flap in the Treatment of Patients with Nasal Valve Dysfunction
S. Bessler (2014)
The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference.
Anna Czapka (2020)
An efficient method based on indoles for the synthesis of isatins by taking advantage of I2O5 as oxidant
Ci-Ping Wang (2017)
TiCl4/DMAP mediated Z-selective knovenagel condensation of isatins with nitroacetates and related compounds
Luyi Zhu (2017)
Design, synthesis and evaluation of semi-synthetic triazole-containing caffeic acid analogues as 5-lipoxygenase inhibitors.
D. De Lucia (2015)
Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents
O. Werz (2017)
Palladium-catalyzed glycosylation: novel synthetic approach to diverse N-heterocyclic glycosides.
Li Ji (2015)
5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease.
O. Rådmark (2015)
Drug Discovery from Mother Nature
S. Gupta (2016)
Inhibitory Effects of Indirubin-3'-oxime Derivatives on Lipid Accumulation in 3T3-L1 Cells.
Yasuhito Nobushi (2020)
Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
R. Filosa (2015)
Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study.
Jing Guo (2017)
Cu–Catalyzed Tandem Oxidation of N‐Substituted Indolines to Isatins
Shanshan Gao (2018)
The Role of Indirubins in Inflammation and Associated Tumorigenesis.
Xinlai Cheng (2016)
5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.
S. Sinha (2019)
A novel small molecule A2A receptor agonist, indirubin-3'-monoxime, alleviates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes.
Saynaz A Choudhary (2019)
Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
L. Yan (2015)
Preliminary pharmacokinetic study of the anticancer 6BIO in mice using an UHPLC‐MS/MS approach
J. Tchoumtchoua (2019)
Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3'-methoxy-4'-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents.
Kishna Ram Senwar (2016)
Antiviral activity of [1,2,3]triazolo[4,5‐d]pyrimidin‐7(6H)‐ones against chikungunya virus targeting the viral capping nsP1
Alba Gigante (2017)
Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Jessica Roos (2016)
Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase
Y. Zhou (2016)
One step synthesis of indirubins by reductive coupling of isatins with KBH4
Cuiling Wang (2017)
Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds.
Andong Zhou (2017)